Accent Microcell (ACCENTMIC)

FairStock Score: 32/100 — RISKY

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 23.66% indicates strong capital efficiency.
• Piotroski F-Score of 7/9 points to solid operating and financial health.
• Promoter holding of 55.47% aligns management interests with minority shareholders.
• Sales growth of 10.58% and profit growth of 9.71% show steady, if moderate, expansion.

Concerns

• P/E of 24.26 with a PEG of 2.39 suggests the price is expensive relative to the recent growth rate.
• FairStock Score of 32/100 labels the stock as risky.
• Missing book value, ROE, and debt/equity data limits a proper margin-of-safety assessment.
• Wide 52-week range of ₹238-₹585 and a dividend yield of only 0.29% provide little downside protection or income support.

AI Analysis

Whenever I look at a pharmaceutical business, I first ask what durable advantage protects its earnings. Accent Microcell has a return on capital employed of 23.66%, which is impressive, and a Piotroski score of 7 out of 9, which suggests the financial fabric is not frail. Promoter holding of 55.47% is another plus because it keeps management's money alongside mine. But a good checklist is not a moat, and moats are what make earnings predictable. At ₹431.80, I am being asked to pay 24.26 times trailing earnings. Revenue grew 10.58% and profit grew 9.71%, so the PEG ratio is about 2.39. That means the price is more than twice as expensive as the growth rate, and Graham taught me never to buy growth at any price. The latest quarter, with ₹139 Cr sales and ₹18 Cr net profit, looks good, but I must not annualise one quarter blindly; the trailing earnings behind the P/E are noticeably lower, so I need proof this profit level is repeatable. I also notice the data gives no book value, no return on equity, and no debt-to-equity ratio. Without those, I cannot calculate a margin of safety or judge whether the balance sheet can survive a bad patch. The dividend yield of only 0.29% does not compensate me while I wait. The 52-week range of ₹238 to ₹585 shows how violently the stock can swing, and FairStock's score of 32/100 confirms the danger. A 23.66% ROCE is attractive, but at this price and with this little information, discipline tells me to pass. I would rather miss an opportunity than lose capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer